Melissa Katigbak
Los Angeles, CANPI 1336742204
Payments from drug & device makers
Across 171 payments — averaging $26.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$868
- Sumitomo Pharma America, Inc.$434
- Teleflex LLC$390
- Johnson & Johnson$356
- Antares Pharma, Inc.$264
- Urogen Pharma, Inc.$235
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,38096%
- Education$1644%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 34 | $868 |
| Sumitomo Pharma America, Inc. | 23 | $434 |
| Teleflex LLC | 5 | $390 |
| Johnson & Johnson | 7 | $356 |
| Antares Pharma, Inc. | 12 | $264 |
| Urogen Pharma, Inc. | 7 | $235 |
| 180 Medical, Inc. | 8 | $225 |
| Astellas Pharma US Inc | 12 | $205 |
| Bayer | 10 | $189 |
| Tolmar Pharmaceuticals, Inc. | 9 | $168 |
| Progenics Pharmaceuticals, Inc. | 6 | $161 |
| Accord Healthcare, Inc. | 5 | $120 |
| Medtronic | 2 | $105 |
| Boston Scientific | 3 | $89 |
| Tolmar, Inc. | 3 | $65 |
| Myriad Genetic Laboratories, Inc. | 3 | $64 |
| Halozyme Inc | 3 | $60 |
| Novartis | 2 | $58 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $58 |
| Bioprotect Medical, Inc. | 2 | $57 |
| Ferring Pharmaceuticals Inc. | 2 | $55 |
| Convatec Inc. | 2 | $49 |
| Blue Earth Diagnostics | 2 | $45 |
| Pfizer | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Telix Pharmaceuticals | 1 | $35 |
| Olympus America Inc. | 1 | $34 |
| Bluewind Medical | 1 | $31 |
| Endo USA, Inc. | 1 | $24 |
| Photocure Inc | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 114 | $90,834 |
| MyrbetriqMirabegron | 95 | $70,536 |
| Testosterone | 29 | $7,905 |
| Methenamine Hippurate | 46 | $4,123 |
| Silodosin | 51 | $3,844 |
| Tamsulosin Hcl | 234 | $3,265 |
| Estradiol | 58 | $3,094 |
| Oxybutynin Chloride ErOxybutynin Chloride | 81 | $1,855 |
| Dutasteride | 30 | $1,802 |
| Finasteride | 88 | $1,525 |
| Solifenacin Succinate | 48 | $1,502 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 23 | $1,198 |
| Potassium Citrate ErPotassium Citrate | 13 | $876 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 22 | $516 |
| Ciprofloxacin Hcl | 83 | $474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $434 | $90,834114 claims |
| Astellas Pharma US IncMyrbetriq | $205 | $70,53695 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Californiaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.